Apixaban vs Warfarin in Elderly AF With CKD: What the Evidence Shows
Synthesising the ARISTOTLE trial and its renal subgroups, RENAL-AF, AXADIA-AFNET 8, large observational cohorts, and a 2024 meta-analysis to guide anticoagulant choice in elderly patients with atrial fibrillation and chronic kidney disease.
This is an original evidence synthesis. See References for source studies.
One-Minute Takeaway
One-Minute Takeaway
- Strong evidence from the ARISTOTLE trial supports apixaban over warfarin in elderly patients with atrial fibrillation and CKD stages 1–3: apixaban reduced stroke/systemic embolism by 21%, major bleeding by 31%, and all-cause mortality by 11%, with the bleeding advantage actually greater in patients with moderate-to-severe renal impairment (p=0.03 for interaction).
- In advanced CKD (CrCl 25–30 mL/min), ARISTOTLE subgroup data (n=269) showed a 66% reduction in major bleeding with apixaban vs warfarin (HR 0.34, 95% CI 0.14–0.80), with pharmacokinetic profiles within expected ranges despite only 25% renal excretion.
- For end-stage kidney disease on haemodialysis, the RENAL-AF trial (n=154) was stopped early due to enrolment challenges and lacked power, finding similar bleeding rates between apixaban and warfarin. A 2024 meta-analysis of observational studies favoured apixaban, but high-quality RCT evidence remains absent.
- Dose selection is critical: the 2.5 mg twice-daily dose should be reserved for patients meeting ≥2 of three criteria (age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL). Inappropriate dose reduction in CKD patients who do not meet these criteria has been associated with increased stroke risk in observational data. Through 2025.
Why Apixaban vs Warfarin in Elderly AF With CKD Matters
Atrial fibrillation and chronic kidney disease frequently coexist — over half of AF patients have some degree of renal impairment, and CKD patients carry a more than 10-fold higher burden of AF compared with the general population. This overlap creates a clinical dilemma: both conditions independently increase the risk of stroke, yet both also amplify the risk of anticoagulant-related bleeding. The elderly population, already predisposed to falls, polypharmacy, and fluctuating renal function, represents the intersection of these compounding risks.
Warfarin has historically been the only option for these patients, but its narrow therapeutic index, requirement for INR monitoring, and association with vascular calcification in CKD make it particularly problematic in this population. Apixaban’s low renal excretion (25%) and the growing body of evidence in renal subpopulations have positioned it as a potential alternative — but the strength of that evidence varies dramatically by CKD stage.
What Evidence Was Reviewed
This synthesis integrates the pivotal ARISTOTLE trial and its renal subgroup analyses, the RENAL-AF and AXADIA-AFNET 8 randomised trials in haemodialysis patients, large observational cohorts, and a 2024 meta-analysis. Evidence is stratified by CKD stage, reflecting the steeply graded nature of the data.
| Study | Design | n | Population | Key Finding | Quality |
|---|---|---|---|---|---|
| ARISTOTLE (2011) | RCT | 18,201 | AF + ≥1 stroke risk factor; CrCl ≥25 | Apixaban superior: stroke/SE HR 0.79; major bleeding HR 0.69; mortality HR 0.89 | High |
| ARISTOTLE — renal function (2016) | Pre-specified subgroup | 18,201 | Stratified by CrCl >80, 50–80, ≤50 | Greater bleeding reduction in worse renal function (p=0.03 for interaction); eGFR decline slower with apixaban | High |
| ARISTOTLE — CrCl 25–30 (2020) | Post-hoc subgroup | 269 | Advanced CKD (CrCl 25–30 mL/min) | Major bleeding HR 0.34 (95% CI 0.14–0.80); PK within range | Moderate |
| RENAL-AF (2022) | RCT (PROBE) | 154 | AF + ESKD on haemodialysis | Stopped early; bleeding 32% vs 26% (HR 1.20, CI 0.63–2.30); underpowered; warfarin TTR only 44% | Low |
| AXADIA-AFNET 8 (2022) | RCT | 97 | AF + haemodialysis | Apixaban 2.5 mg vs VKA: no significant difference in bleeding or efficacy; median follow-up 462 days | Low |
| AlTurki et al. 2024 MA | Meta-analysis (5 observational) | 10,036 | AF + ESKD on dialysis | Apixaban vs warfarin: major bleeding OR 0.51; stroke/SE OR 0.64; GI bleeding OR 0.61 | Moderate |
| US Medicare cohort (2019) | Retrospective cohort | 22,739 | AF + CKD 3–5 | Apixaban associated with lowest stroke/SE risk among DOACs vs warfarin in CKD | Moderate |
| Chen et al. 2025 (TriNetX) | Retrospective cohort | 2,728 | AF + CKD 5/ESKD | Apixaban: cerebrovascular events SHR 0.69; bleeding SHR 0.75; composite SHR 0.69 vs warfarin | Moderate |
| Siontis et al. 2018 | Retrospective (Medicare) | 25,523 | AF + ESKD on dialysis | Standard-dose apixaban: lower stroke/SE and death vs warfarin; reduced dose: no efficacy benefit, higher mortality | Moderate |
| Halvorsen et al. 2014 | ARISTOTLE subgroup | 18,201 | Stratified by age (<65, 65–74, ≥75) | Consistent apixaban benefit across age groups; absolute bleeding reduction greatest in elderly | High |
Key Findings: Apixaban vs Warfarin Across the CKD Spectrum in Elderly AF
CKD Stages 1–3: Strong RCT Evidence Favouring Apixaban
The ARISTOTLE trial provides the foundational evidence. Among 18,201 participants with AF, apixaban 5 mg twice daily (or 2.5 mg with dose-reduction criteria) was superior to warfarin for stroke/systemic embolism prevention (HR 0.79, 95% CI 0.66–0.95), caused less major bleeding (HR 0.69, 95% CI 0.60–0.80), and reduced all-cause mortality (HR 0.89, 95% CI 0.80–0.998). Pre-specified renal subgroup analyses demonstrated that the bleeding advantage of apixaban over warfarin was actually more pronounced as renal function declined (p=0.03 for interaction), with the greatest relative bleeding reduction in patients with CrCl ≤50 mL/min. A secondary analysis also found that apixaban was associated with slower eGFR decline over time compared with warfarin — a finding consistent with the known nephrotoxic effects of warfarin-related vascular calcification.
CKD Stage 4 (CrCl 25–30 mL/min): Encouraging But Limited Data
The post-hoc ARISTOTLE subgroup analysis by Stanifer et al. (2020) examined 269 patients with CrCl 25–30 mL/min — the lower boundary of ARISTOTLE’s eligibility criteria. Despite the small sample, apixaban demonstrated a striking 66% reduction in major bleeding (HR 0.34, 95% CI 0.14–0.80) and 65% reduction in major or clinically relevant non-major bleeding (HR 0.35, 95% CI 0.17–0.72) compared with warfarin. Pharmacokinetic modelling showed that apixaban drug exposure in this subgroup, while modestly higher than in patients with preserved renal function, remained within the clinically observed range from the overall ARISTOTLE population. These data are reassuring but derive from a small, post-hoc analysis and should not be over-interpreted.
End-Stage Kidney Disease on Haemodialysis: Evidence Gap Persists
The two RCTs in haemodialysis patients — RENAL-AF (n=154) and AXADIA-AFNET 8 (n=97) — both stopped early and were severely underpowered. RENAL-AF found bleeding rates of 32% with apixaban versus 26% with warfarin over a median of 11 months (HR 1.20, 95% CI 0.63–2.30) — with no meaningful conclusion possible. Warfarin control was poor (TTR only 44%), making comparisons unreliable. AXADIA compared apixaban 2.5 mg twice daily against VKA and similarly found no significant differences, but enrolled only 97 patients. Both trials underscore the extreme difficulty of conducting adequately powered RCTs in this medically complex population.
The 2024 meta-analysis by AlTurki et al., pooling five observational studies of 10,036 dialysis patients, found that apixaban was associated with reduced major bleeding (OR 0.51, 95% CI 0.42–0.61), intracranial bleeding (OR 0.58), GI bleeding (OR 0.61), and stroke/systemic embolism (OR 0.64) compared with warfarin. A 2025 TriNetX cohort analysis (n=2,728) similarly favoured apixaban across effectiveness and safety endpoints. While these data are directionally encouraging, they are observational and subject to confounding.
Apixaban dosing in CKD requires meeting ≥2 of three criteria for dose reduction to 2.5 mg twice daily: age ≥80 years, body weight ≤60 kg, and serum creatinine ≥1.5 mg/dL. Renal function alone does not trigger dose reduction. In secondary ARISTOTLE analyses, standard-dose apixaban (5 mg twice daily) reduced stroke/SE by 23% versus warfarin, whereas the reduced dose showed no significant stroke reduction. A landmark 2018 Medicare study by Siontis et al. found that among dialysis patients, those prescribed standard-dose apixaban (5 mg twice daily) had lower rates of stroke and death than those on warfarin, but reduced-dose apixaban (2.5 mg twice daily) was associated with no stroke benefit and higher mortality — likely due to inappropriate dose reduction leaving patients sub-therapeutically anticoagulated. This finding has important implications: applying dose reduction based on CKD alone, without meeting the multi-criteria threshold, may cause harm.
Beyond bleeding and INR instability, warfarin carries a specific risk in CKD that is absent with apixaban: promotion of vascular calcification. Warfarin inhibits vitamin K-dependent activation of matrix Gla protein, a key inhibitor of vascular calcification. In patients with CKD — who already have a massively elevated calcification burden — this effect may accelerate arterial stiffness, calciphylaxis, and cardiovascular death. The ARISTOTLE subgroup analysis showing slower eGFR decline with apixaban compared with warfarin may reflect, in part, the avoidance of warfarin-related renal vascular injury. While this remains hypothesis-generating, it provides additional biological rationale for preferring apixaban in CKD populations.
Halvorsen et al.’s age-stratified ARISTOTLE analysis confirmed that apixaban’s benefits over warfarin were consistent across patients aged <65, 65–74, and ≥75 years. The absolute benefit was greatest in elderly patients because of their higher baseline event rates. In patients ≥75, the reduction in intracranial haemorrhage — the most feared bleeding complication — was particularly relevant given the age-related increase in this risk. Importantly, apixaban does not require routine monitoring or dose adjustment for age alone, reducing the burden of anticoagulation management in elderly patients who may have cognitive impairment, mobility limitations, or difficulty attending INR clinics. The combination of predictable pharmacokinetics, low renal excretion, and no monitoring requirement makes apixaban pragmatically advantageous for elderly CKD patients.
Several ongoing RCTs may address the ESKD evidence gap. AVKDIAL (n=855, NCT02886962) and DANWARD (n=718, NCT03862859) are comparing VKA with no anticoagulation in dialysis patients and are powered for clinical outcomes — these will address the fundamental question of whether any anticoagulation benefits this population. SAFE-D (n=150, NCT03987711) is a three-arm trial comparing apixaban, warfarin, and no anticoagulation. The Swedish SACK trial is evaluating apixaban in CKD stage 5 patients. Until these results are available, the evidence base for anticoagulant choice in AF with ESKD on dialysis remains insufficient for definitive recommendations.
Quality & Consistency of Evidence
What the Evidence Does NOT Show
Despite ARISTOTLE’s robust renal subgroup data, critical questions remain unanswered for the most vulnerable patients.
Adequately powered ESKD comparison: Neither RENAL-AF nor AXADIA achieved their target enrolment. No RCT has definitively established whether apixaban is safer or more effective than warfarin in haemodialysis patients. Current guideline recommendations in this population are based on FDA pharmacokinetic approval, observational data, and extrapolation rather than outcome trial evidence.
Anticoagulation vs no anticoagulation in ESKD: The fundamental question of whether stroke prevention anticoagulation provides net clinical benefit in dialysis patients with AF — where bleeding rates approach 25–30% annually and ischaemic stroke rates are only 3% — remains unresolved. AVKDIAL and DANWARD are designed to address this, but results are pending.
Long-term outcomes beyond 2 years in advanced CKD: ARISTOTLE’s median follow-up was 1.8 years. Whether apixaban’s advantages are sustained in patients with progressive CKD over 5–10 years — accounting for potential drug accumulation as renal function declines — has not been studied.
Optimal dosing strategy in CKD stage 4–5: The RENAL-AF pharmacokinetic substudy found that apixaban 2.5 mg twice daily in dialysis patients produced exposure comparable to the standard 5 mg dose in patients with preserved renal function. However, an earlier study found that 5 mg twice daily produced supratherapeutic levels. The optimal dose for ESKD patients who do not meet multi-criteria dose-reduction requirements remains debated.
Practical Implications
Based on the current evidence, the following considerations emerge for clinicians managing anticoagulation in elderly patients with AF and CKD.
ARISTOTLE provides high-quality evidence that apixaban is superior to warfarin for stroke prevention and bleeding reduction in AF patients with CrCl >30 mL/min, with the bleeding advantage amplified as renal function worsens. Apixaban should be the preferred anticoagulant in this population unless specific contraindications exist (e.g., mechanical heart valve, severe mitral stenosis).
The ARISTOTLE CrCl 25–30 subgroup and supportive pharmacokinetic data suggest apixaban is safe at this level of renal impairment. While the data are limited to 269 patients in a post-hoc analysis, the direction and magnitude of benefit are consistent with the overall trial. The available evidence supports apixaban use down to CrCl 25 mL/min.
The dose-reduction criteria (≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) must be applied rigorously. The available evidence indicates that inappropriate dose reduction based on CKD alone leads to sub-therapeutic anticoagulation and may increase stroke risk. Renal function should be monitored at least every 6–12 months to detect clinically significant decline.
The evidence is insufficient to make a definitive recommendation for or against apixaban over warfarin — or indeed whether to anticoagulate at all — in dialysis patients with AF. Shared decision-making incorporating individual stroke risk (CHA₂DS₂-VASc), bleeding risk (HAS-BLED), life expectancy, and patient preferences is essential. Results of AVKDIAL, DANWARD, and SAFE-D are awaited.
Evidence Grade & Bottom Line
Evidence Grade: Strong (CKD 1–3) · Moderate (CKD 4) · Insufficient (ESKD/dialysis)
The evidence grades are stratified by CKD stage because the quality and quantity of data differ markedly. For CKD stages 1–3, ARISTOTLE provides definitive evidence. For advanced CKD, the evidence is promising but limited. For ESKD on dialysis, adequately powered trials are lacking and clinical equipoise persists.
In elderly AF patients with CKD stages 1–3, apixaban should replace warfarin as the standard of care. In CKD stage 4, apixaban appears to be the most appropriate DOAC based on its pharmacokinetic profile and limited outcome data. In ESKD on dialysis, the decision to anticoagulate and the choice of agent should be made through individualised shared decision-making until definitive trial results become available.
- Apixaban is superior to warfarin for stroke prevention and bleeding reduction in elderly AF patients with CKD stages 1–3, with the bleeding advantage amplified by worsening renal function
- In advanced CKD (CrCl 25–30), ARISTOTLE subgroup data show a 66% major bleeding reduction with apixaban and pharmacokinetics within acceptable range
- Apixaban’s 25% renal excretion — lowest of any DOAC — provides the pharmacokinetic basis for its safety profile in renal impairment
- Inappropriate dose reduction (2.5 mg without meeting ≥2 criteria) has been associated with increased stroke and mortality in observational data — correct dosing is essential
- For ESKD on dialysis, the evidence base remains insufficient: two underpowered RCTs and observational data cannot establish definitive superiority, and whether anticoagulation provides net benefit in this population is unknown
Article Information
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. DOI: 10.1056/NEJMoa1107039
- Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation. Eur Heart J. 2012;33(22):2821-2830. DOI: 10.1093/eurheartj/ehs274
- Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time. JAMA Cardiol. 2016;1(4):451-460. DOI: 10.1001/jamacardio.2016.1170
- Stanifer JW, Pokorney SD, Chertow GM, et al. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation. 2020;141(19):1384-1392. DOI: 10.1161/CIRCULATIONAHA.119.044059
- Pokorney SD, Chertow GM, Al-Khalidi HR, et al. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation. 2022;146(23):1735-1745. DOI: 10.1161/CIRCULATIONAHA.121.054990
- Reinecke H, Engelbertz C, Bauersachs R, et al. A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation. 2023;147(4):296-309. DOI: 10.1161/CIRCULATIONAHA.122.062779
- AlTurki A, Marafi M, Russo V, et al. Meta-analysis evaluating apixaban in patients with atrial fibrillation and end-stage renal disease requiring dialysis. J Arrhythm. 2024;40(3):567-575. DOI: 10.1002/joa3.13051
- Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018;138(15):1519-1529. DOI: 10.1161/CIRCULATIONAHA.118.035418
- Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation. Eur Heart J. 2014;35(28):1864-1872. DOI: 10.1093/eurheartj/ehu046
- Chen YJ, Lee CJ, Hsu YC, et al. Effectiveness and safety of apixaban and warfarin in patients with new-onset atrial fibrillation after advanced CKD or ESKD. Am J Kidney Dis. 2025;[Epub ahead of print]. DOI: 10.1053/j.ajkd.2024.12.012
- Benz AP, Eikelboom JW. Apixaban compared with warfarin in patients with atrial fibrillation and end-stage renal disease: lessons learned. Circulation. 2022;146(23):1746-1748. DOI: 10.1161/CIRCULATIONAHA.122.061647
- Lin YC, Chen YC, Chiang CE, et al. Apixaban vs. warfarin in atrial fibrillation patients with chronic kidney disease. Front Cardiovasc Med. 2021;8:752468. DOI: 10.3389/fcvm.2021.752468